| Autor: |
Jonathon R Campbell, Edward D Chan, Dennis Falzon, Anete Trajman, Salmaan Keshavjee, Chi C Leung, Ann C Miller, Ignacio Monedero-Recuero, Denise S Rodrigues, Haesook Seo, Parvaneh Baghaei, Zarir Udwadia, Piret Viiklepp, Mayara Bastos, Dick Menzies |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. |
| ISSN: |
1537-6591 |
| Popis: |
Background The impact of low body mass index (BMI) at initiation of rifampicin-resistant tuberculosis (RR-TB) treatment on outcomes is uncertain. We evaluated the association between BMI at RR-TB treatment initiation and end-of-treatment outcomes. Methods We performed an individual participant data meta-analysis of adults aged ≥18 years with RR-TB whose BMI was documented at treatment initiation. We compared odds of any unfavorable treatment outcome, mortality, or failure/recurrence between patients who were underweight (BMI Results Overall, 5148 patients were included; 1702 (33%) were underweight at treatment initiation. The median (interquartile range) age was 37 years (29 to 47), and 455 (9%) had HIV. Compared with nonunderweight patients, the aOR among underweight patients was 1.7 (95% CI, 1.4–1.9) for any unfavorable outcome, 3.1 (2.4–3.9) for death, and 1.6 (1.2–2.0) for failure/recurrence. Significant effect modification was found for World Health Organization region of treatment. Among HIV-negative patients, 24-month mortality was 14.8% (95% CI, 12.7%–17.3%) for underweight and 5.6% (4.5%–7.0%) for not underweight patients. Among patients with HIV, corresponding values were 33.0% (25.6%–42.6%) and 20.9% (14.1%–27.6%). Conclusions Low BMI at treatment initiation for RR-TB is associated with increased odds of unfavorable treatment outcome, particularly mortality. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
